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Abstract
SETD8/SET8/Pr-SET7/KMT5A is the only known lysine methyltransferase (KMT) that monomethylates lysine 20 of
histone H4 (H4K20) in vivo. Lysine residues of non-histone proteins including proliferating cell nuclear antigen
(PCNA) and p53 are also monomethylated. As a consequence, the methyltransferase activity of the enzyme is
implicated in many essential cellular processes including DNA replication, DNA damage response, transcription
modulation, and cell cycle regulation. This review aims to provide an overview of the roles of SETD8 in
physiological and pathological pathways and to discuss the progress made to date in inhibiting the activity of
SETD8 by small molecules, with an emphasis on their discovery, selectivity over other methyltransferases and
cellular activity.
Background
Lysine methylation on histone tails is a prevalent post-
translational modification and, together with arginine
methylation, plays a primary role in the regulation of
chromatin structure and gene transcription, both in
physiological and pathological conditions [1–5]. A large
body of evidence indicates the importance of lysine
methylation not only in epigenetic regulation of gene
expression but also in the regulation of cellular signal
transduction pathways [6, 7]. In fact, in addition to
histones, a number of non-histone proteins are also
methylated on Lys residues, leading to changes in their
function or stability [7, 8]. Methylation increases the
hydrophobic and basic nature of the lysine residue,
which allows other proteins to recognize methylated
lysine.
There are three different forms of methylated lysines,
monomethyl-, dimethyl-, and trimethyl-lysines [9], each
one being produced by certain specific protein lysine
methyltransferases (PKMTs or KMTs, Fig. 1) that
catalyze the addition of a methyl group from S-adeno-
syl-L-methionine (SAM) to the ε-amine group of the
side chain of a particular lysine residue [9]. Most KMTs
contain the SET (Su(var), Enhancer of zeste, Trithorax)
domain and are thought to catalyze a sequential bi-bi
kinetic mechanism in which both substrate association
and product release occur in a random manner [9]. Yet,
numerous non-SET-domain proteins such as DOT1L
and methyltransferase-like (METTL) proteins (Fig. 1)
also have lysine N-methyltransferase activity [10, 11].
Many disease conditions, including cancer, have been
associated with dysregulation of protein methylation
and, indeed, there are a large number of reports describ-
ing that abnormal KMT activity drives cancer tumori-
genesis or neurodegenerative diseases [12–15].
SETD8 (also known as PR-SET7, SET8, or KMT5A), a
member of the SET domain containing family, is unique
among the several KMTs identified so far because it is
the sole mammalian enzyme known to catalyze the
monomethylation of histone H4 Lys20 (H4K20me1,
Fig. 1) [16, 17], a modification that may be involved in
the recruitment of signaling proteins like 53BP1 to site
of double-strand DNA breaks [18] or directly modulate
chromatin compaction [19]. H4K20 methylation plays
key roles in DNA replication, DNA damage repair, and
silenced hetereochromatin [17, 20–22]. Consequently,
there is a significant interest in the precise mechanistic
role of this modification and the enzymes responsible
for installing the methyl marks.
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Here, we provide a summary of the most important
activities of SETD8 in physiological and pathological
pathways together with a comprehensive overview of
SETD8 modulators (Tables 1 and 2).
SETD8 roles in physiology and pathology
SETD8 targets
Differently from other KMTs, SETD8 prefers nucleo-
somes as substrates over histone proteins or peptides
[16, 23], and this hints that the enzyme must interact
with other surfaces of the nucleosome in addition to the
H4 N-terminal region surrounding the targeted H4K20
residue. As a matter of fact, Tan and coworkers recently
showed that the enzyme binds and methylates nucleo-
some substrates using multivalent interactions [24]. In
fact, SETD8 uses at least three distinct regions to
interact with the nucleosome substrate (Fig. 2). A basic
N-terminal region is the primary determinant of such
binding and interacts with a cluster of eight acidic resi-
dues of the nucleosomal H2A/H2B histone dimer (E56,
E61, E64, D90, E91, E92 of H2A and E102, E110 of H2B)
that forms a negatively charged “acidic patch” having the
shape of a narrow groove [25]. The same basic N-ter-
minal region of SETD8 likely interacts also with nucleo-
somal DNA (together with i-SET and c-SET domains) to
anchor the methyltransferase to the nucleosome. This
places the SET domain for interaction with the nucleo-
some face close to the targeted methylation site. Subse-
quently, the enzyme catalytic site engages the H4 tail
and methylates lysine 20 [24].
Besides H4K20, SETD8 also methylates lysine residues
of many other proteins, including p53 and PCNA (Fig. 3).
Gozani and coworkers reported that the enzyme mono-
methylates p53 at lysine 382 (p53K382me1) and that this
methylation suppresses p53-dependent transcription
activation in cancer cells [26]. The apoptotic pathway
mediated by p53 is further regulated by SETD8 through
the methylation of Numb, a protein existing in multiple
isoforms in mammals and that was shown to form a tri-
partite complex with p53 and the E3 ubiquitin ligase
Fig. 1 Phylogenetic tree of protein methyltransferases (PMTs; obtained with the Structural Genomic Consortium ChromoHub [102] and modified
with Adobe Illustrator CS5). Specific modifications induced on histones H3 (shades of blue) and H4 (shades of green) are also shown. SETD8 is
highlighted with a rubine red asterisk
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Table 1 SETD8 roles in physiological and pathological pathways
Physiological/pathological pathways Roles of SETD8 References
Cell cycle progression A direct role in the regulation of ORIs [44]
Upregulated in G2/M and early G1, nearly absent in S phase [17, 20, 35–40]
SETD8 ubiquitin-mediated degradation is required for the onset of S phase [34, 36–42]
Transcriptional regulation Promotes transcriptional repression [31, 42, 55–57]
Mediates transcriptional activation [20, 45, 52–54]
Regulation of DNA replication Binds to the H4 N-terminal tail and blocks the acetylation of H4K5, H4K8 and H4K12 during G1, hindering DNA replication [41]
DNA damage response SETD8 methyltransferase activity during the DNA damage response is necessary to recruit 53BP1 for efficient DNA repair
and checkpoint activation; enzyme depletion leads to an increase in spontaneous DNA damage
[18, 20, 49]
Regulation of p53 activity Catalyzes p53 monomethylation (p53K382me1), suppressing p53-dependent transcription activation in cancer cells [26]
Methylates Numb (K158 and K163), thus uncoupling it from p53 and increasing p53 ubiquitination and degradation [27]
Regulation of PCNA Monomethylates PCNA (PCNAK248me1), thus stabilizing PCNA proteins through inhibition of polyubiquitylation and
enhancing the interaction between PCNA and the flap endonuclease FEN1
[28]
Cancer Overexpressed in different types of cancer tissues and cancer cell lines including bladder cancer, non-small cell and small
cell lung carcinoma, chronic myelogenous leukemia, hepatocellular carcinoma, and pancreatic cancer
[28]
SETD8-mediated p53K382me1 suppresses p53-dependent transcription activation in cancer cells [26]
SETD8-dependent monomethylation of PCNAK248 promote tumorigenesis [28]
Implicated in cancer invasiveness and metastasis through its interaction with TWIST [60]
Direct target of miRNA miR-127-3p, influencing OS progression and metastasis [62]
Reduced SETD8 expression by polymorphism rs16917496 T > C is associated with decreased susceptibility to different
types of cancer (breast and ovarian cancer, SCLC, hepatocellular carcinoma, NSCLC, childhood ALL)
[63–68]
miR-7-promoted SETD8 mRNA degradation inhibits H4K20 monomethylation and suppresses EMT and invasion of
breast cancer cells
[61]
Crucial for AR-mediated transcription activation of PSA gene [69]
SETD8 binding interaction is required for PRDM2 tumor suppressor function [70]
Regulation of erythroid cells maturation SETD8 is a repressor of endothelial transcription factor GATA-2 expression and regulates erythroid maturation and
promotes the maturation and survival of definitive erythroblasts
[72–74]
Maintenance of adult skin Loss of SETD8 results in loss of proliferation and impaired differentiation, accompanied by loss of the interfollicular
epidermis and sebaceous glands
[75]
Regulation of adipogenesis Upregulation of Setd8 gene by PPARγ promotes adipogenesis, while gene knockdown suppresses it [52]
Neurodevelopmental disorders IUGR induces a reduction of PPARγ-SETD8-H4K20me1 and Wnt signaling, thus causing impaired neurodevelopment











Table 2 SETD8 inhibitors
compound structure Enzyme activity Biological effects Ref.
H acid IC50 = 3.8 μM also inhibits EZH2 (3.0 μM); no
inhibition of G9a, SETD7 and PRMT1
Not cell permeable [79]
Thymolphthalein IC50 = 9.0 μM also inhibits EZH2 (25.2 μM); no
inhibition of G9a, SETD7 and PRMT1
Marked concentration-dependent effect on HeLa
cells viability; evident reduction of H4K20me1;
does not affect other histone methylation marks;
possible interference with the binding to the
nucleosome
[79]
EBI-099 IC50 = 4.7 μM no inhibition of G9a Antiproliferative effects against human




IC50 = 3.3 μM and 2.6 μM, respectively; no
inhibition of EZH2, G9a and SETD7
Both compounds (50 μM) reduce H4K20me1











Table 2 SETD8 inhibitors (Continued)
MC1947
MC2569
Dual inhibitors of SETD8 (IC50 = 9.0 μM and 10.2
μM, respectively) and EZH2 (IC50 = 74.9 μM and
313.8 μM, respectively); no inhibition of G9a and
SETD7
Both compounds (50 μM) reduce H4K20me1 in
U937 cells; MC1947 induces massive cell death
and increases granulocytic differentiation; possible
covalent inhibition
[86]
Nahuoic acid A IC50 = 6.5 μM no inhibition of G9a, EHMT1, SETD7,
SUV39H2, SUV420H1, SUV420H2, DOT1L, PRMT3,
PRMT5 and MLL complexes
SAM-competitive and substrate-noncompetitive;
the compound inhibits SETD8 in U2OS
osteosarcoma cells
[87, 88]
UNC0379 IC50 = 7.3 μM no inhibition of G9a, SETDB1, GLP,
SUV39H2, SETD7, PRMT3, PRMT5-MEP50 complex,
PRMT1, SUV420H1, SUV420H2, SMYD2, DNMT1, PRC2
complex, MLL1 complex, and DOT1L
Substrate-competitive and SAM-noncompetitive; no
cellular activity reported
[95, 96]
SPS8I1 (NSC663284) IC50 = 0.21 μM inhibits SETD2, G9a, SMYD2, CARM1,
and PRMT3 with IC50 values in the low micromolar
or submicromolar range; no inhibition of GLP, SETD7,
PRMT1
Substrate-dependent and irreversible inhibitor of
SETD8; reduces H4K20me1 in HEK293T cells and
produces a cell cycle arrest phenotype; off-target
inhibition of Cdc25
[97]
SPS8I2 (Ryuvidine) IC50 = 0.50 μM inhibits GLP, SETD2, G9a, SMYD2,
CARM1, and PRMT3 with IC50 values in the low
micromolar or submicromolar range; no inhibition
of SETD7, PRMT1
Substrate- and cofactor independent; irreversible
inhibitor of SETD8; reduces H4K20me1 in HEK293T
cells and produces a cell cycle arrest phenotype;












Table 2 SETD8 inhibitors (Continued)
SPS8I3 (BVT948) IC50 = 0.70 μM inhibits SETD2, G9a, SMYD2, CARM1,
and PRMT3 with IC50 values in the low micromolar
or submicromolar range; no inhibition ofGLP, SETD7,
PRMT1
Substrate- and SAM-dependent; irreversible inhibitor
of SETD8; reduces H4K20me1 in HEK293T cells and
produces a cell cycle arrest phenotype; off-target





Inhibit SETD8 with IC50 values≤ 5 μM also inhibit
SETD2, SETDB1, GLP, G9a, SMYD2, SMYD3, MLL1,












MDM2 [27]. Numb promotes apoptosis in a p53-
dependent manner, but the apoptotic function is
abolished when Numb is methylated by SETD8 on the
K158 and K163 residues contained in its phosphotyro-
sine binding (PTB) domain. Such methylation uncouples
Numb from p53, resulting in increased p53 ubiquitina-
tion and degradation [27]. Also, Hamamoto and
coworkers reported that SETD8 monomethylates lysine
248 of PCNA (PCNAK248me1), thus stabilizing PCNA
proteins through inhibition of polyubiquitylation and
substantially enhancing the interaction between PCNA
and the flap endonuclease FEN1 [28].
SETD8 interactors and regulation
Within cells, SETD8 specifically localizes to mitotic
chromosomes. In particular, it colocalizes with SIRT2 at
mitotic foci. During mitosis, the association of the
enzyme with chromosomes is increased in a H2O2-
induced oxidative stress-dependent manner. Also, the
protein associates with silent chromatin on euchromatic
arms, whereas it does not associate with constitutive
heterochromatin [29–33].
The regulation of H4K20me1 mediated by SETD8
during distinct cell cycle phases is essential for proper
cell cycle progression as well as in the DNA damage
response, and it was found associated with mitotic chro-
mosomes during cell division. Recent data demonstrate
a direct involvement of H4K20me1 modification in the
assembling of the pre-replication complex (pre-RC) on
the replication origins (ORIs) of metazoans [34]. Knock-
out of SETD8 and subsequent loss of H4K20me1 induce
abnormalities in cell cycle progression and impaired
nuclear condensation and are embryonic lethal preim-
plantation at approximately the 4- to 8-cell stages [35].
Also, SETD8 protein expression is tightly regulated dur-
ing the cell cycle, being highest during G2/M (when it is
Fig. 2 SETD8 protein structure. a Cartoon showing the C-terminal core SET domain and the locations of the n-SET, i-SET, and c-SET regions
(obtained with). b Crystal structure of the SETD8 SET domain (tan), showing bound H4 peptide and substrate residue Lys20 (orange), n-SET (blue),
i-SET (dark red), c-SET (dark green) regions, and product cofactor S-adenosyl homocysteine (SAH; white). The picture was prepared using Illustrator
for Biological Sequences (IBS) [103] (panel a) and UCSF Chimera [104] (panel b, coordinates from Protein Data Bank (PDB) ID code 1ZKK, chain A)
and modified with Adobe Illustrator CS5
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targeted to ORIs to place H4K20me1) and early G1 and
nearly absent during S phase [17, 20, 35–40]. During G1
and G2 phases, the enzyme is concentrated in the nu-
cleus and is excluded from it during S phase. At G1/S
transition, SETD8 is degraded by the proteasome
through DCXDTL (also known as CRL4Cdt2) and SCFβ-
TRCP ubiquitin-mediated destruction, this degradation
being required for the onset of S phase [34, 36–42].
(Wang) One of the two proliferating cell nuclear antigen
(PCNA)-interacting domains carried by SETD8 is
required for degradation of the enzyme [43]. Preventing
SETD8 degradation in the S phase results in the accu-
mulation of SETD8 at foci that co-localize with markers
of active replicating forks (BrdU, PCNA, and DNA poly-
merase ε), further supporting a direct role for SETD8 in
the regulation of ORIs [44].
Li and coworkers showed that SETD8 is directly
involved into Wnt/β-catenin signaling, which plays an
important role in a wide range of biological and patho-
physiological processes [45]. They found that, under
Wnt3a stimulation, the enzyme is recruited by lymphoid
enhancing factor-1 (LEF1)/TCF4 to regulate the transcrip-
tion of Wnt-activated genes, possibly through H4K20
monomethylation at the target gene promoters.
Chang and coworkers reported that SETD8 suppress
DNA replication through histone binding. They showed
that during G1, the enzyme binds to hypoacetylated but
not hyperacetylated H4 N-terminal tail and blocks the
acetylation of lysine residues K5, K8, and K12 of histone
H4. Such a blockage can hinder DNA replication [41].
DNA damage response is a signaling pathway activated
by DNA double-strand breaks which recruit signaling
proteins to chromatin flanking the lesion via protein–
protein interactions and post-translational modifications.
H4K20 methylation is implicated in the DNA damage
response in diverse organisms and in an evolutionarily
conserved manner. In mammalian cells, depletion of
SETD8 results in the formation of γH2AX foci (a hall-
mark of DNA damage) and increased sensitivity to a
variety of genotoxic stresses, due to defects during DNA
replication or mitosis and consequent genomic instabil-
ity [20, 35, 46]. The recruitment of factors involved in
the DNA damage response involves the interaction
between histone modifications and specific reader
domains, typically containing a hydrophobic pocket
made up of two to four aromatic residues that can
discriminate between the site and the degree of methyla-
tion by interacting with the methylated lysine as well as
making additional contacts with the sequence surround-
ing the methylated residue [47, 48]. Both H4K20me1
and H4K20me2 are bound by a conserved tandem tudor
domain contained in 53BP1, a key protein in DNA
Fig. 3 SETD8 protein–protein interaction network, obtained with Cytoscape v. 3.4.0 [105] using STRING database [106]. Only proteins directly
interacting with SETD8 are displayed as colored glass-like marbles: histone cluster 1, H4a (HIST1H4a, red), lymphoid enhancer-binding factor 1
(LEF1, aquamarine), proliferating cell nuclear antigen (PCNA, violet red), denticleless protein homolog (DTL, also known as CDT2, persian blue),
tumor protein p53 (p53, tan), protein numb homolog (NUMB, green). SETD8 is depicted in orchid. Direct interactions of SETD8 with protein targets
leading to post-translational modifications are depicted as orange arrows, protein–protein interactions leading to SETD8 degradation as lime
arrows, binding interactions as cornflower lines. Other interactions are shown as gray lines. Interactions of SETD8 with proteins PLOD1–3
(procollagen-lysine, 2-oxoglutarate 5-dioxygenase, shades of gray) were also retrieved from the interrogation of the STRING database, yet we
found no evidence in the literature. Therefore they are shown as dotted gray lines
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damage-signaling pathways that associates with sites of
DNA damage at an early stage in the repair pathway
[49]. Reinberg and coworkers showed that SETD8 is
rapidly recruited to sites of DNA double-strand breaks
through its binding to PCNA, inducing a prompt
increase of H4K20me1 that is necessary to recruit
53BP1, functioning as a scaffolding protein for efficient
DNA repair and checkpoint activation [20]. SETD8
methyltransferase activity during the DNA damage
response is required for recruitment of 53BP1 [18].
Since it is enriched during mitosis, H4K20me1 repre-
sents a specific tag for epigenetic transcriptional regula-
tion [16, 23, 30, 33, 50, 51]. However, regardless of
numerous studies examining its role, this modification
still has an uncertain function in gene expression, with
evidence supporting a correlation with both gene expres-
sion and repression [20, 40]. Some gene-specific
analyses, together with genome-wide ChIP studies, have
associated H4K20me1 with active transcription [20, 45,
52–54], while a subset of non-genome-wide ChIP along
with biochemical studies have correlated H4K20me1
with gene repression [31, 42, 55–57].
These apparently contradictory experimental results
suggest that the impact of SETD8 on gene expression
may be genomic- and/or cellular context-dependent. For
instance, neighboring modifications on the H4 tail like
as H4K16 acetylation (H4K16ac) may affect H4K20me1
function [20]. Recently, it has been shown that SETD8-
mediated monomethylation of H4K20me regulates RNA
polymerase II (Pol II) pausing dynamics and can func-
tion in both gene activation and repression [58]. In fact,
H4K20me1 promotes the local recruitment of the MSL
complex and acetylation of H4K16, thus inducing the
release of RNA polymerase II (Pol II) into active elong-
ation. In the absence of SETD8, MSL recruitment and
H4K16Ac levels are locally down-regulated, Pol II paus-
ing is induced, and gene expression is down-regulated.
On the other hand, H4K20me1 serves as a substrate for
SUV420H2-mediated H4K20me3 and imposes Pol II
pausing. Down-regulation of SETD8 results in the local
depletion of H4K20me2/3 at genes controlled by an
H4K20me3-mediated pause but does not result in relief
of paused Pol II because of an inability to recruit MSL
in the absence of H4K20me1 [58].
SETD8 in pathology and physiology
As recently demonstrated by Hamamoto and coworkers,
SETD8 is overexpressed in different types of cancer
tissues and cancer cell lines including bladder cancer,
non-small cell and small cell lung carcinoma, chronic
myelogenous leukemia, hepatocellular carcinoma and
pancreatic cancer [28]. They also reported that reduction
or loss of SETD8-mediated methylation of PCNA signifi-
cantly suppresses the growth of cancer cells by retarding
the maturation of Okazaki fragments and slowing DNA
replication, and demonstrated a correlation between the
expression levels of SETD8 and PCNA in human cancer
tissues [28]. Since PCNA has been widely recognized as
a tumor marker for cancer progression and poor patient
prognosis [59], SETD8-dependent PCNA methylation is
likely to promote tumorigenesis. Similarly, SETD8 is
overexpressed in different types of cancer tissues and
cancer cell lines including bladder cancer, non-small cell
and small cell lung carcinoma, chronic myelogenous
leukemia, hepatocellular carcinoma and pancreatic can-
cer [28].
Moreover, SETD8 is implicated in cancer invasiveness
and metastasis through its interaction with TWIST, a
master regulator in epithelial–mesenchymal transition
(EMT) [60]. It has been shown that SETD8 and TWIST
are functionally interdependent in promoting EMT and
enhancing the invasive potential of breast cancer cells in
vitro and in vivo. Also, the KMT enzyme acts as a dual
epigenetic modifier on the promoters of E-cadherin and
N-cadherin the target genes of TWIST. Interestingly, the
down-regulation of SETD8 by shRNA in breast cancer
cells suppresses cell intravasation and spontaneous lung
metastasis in an orthotopic mouse model [60]. Sun and
coworkers reported that a microRNA (miRNA), miR-7,
is a negative regulator of SETD8, inhibits H4K20 mono-
methylation, and suppresses EMT and the invasive po-
tential of breast cancer cells [61]. MiRNAs are a class of
small (∼20–22 nt) non-coding RNA molecules that regu-
late gene expression through binding the 3′-untranslated
region (3′UTR) of targeted mRNA. The authors demon-
strated that SETD8 is a downstream target of miR-7 that
binds to SETD8 3′-UTR and inhibits the formation of
H4K20me1 by promoting SETD8 mRNA degradation.
This interaction suppresses EMT and invasion of breast
cancer cells [61].
SETD8 has been also identified as a direct target of
miR-127-3p, a miRNA that acts as a tumor suppressor
in osteosarcoma (OS) tissues and cell lines and whose
down-regulation in cancer may contribute to OS pro-
gression and metastasis. MiR-127-3p has been suggested
to act mainly via the suppression of SETD8 expression.
SETD8 overexpression can reverse the potential influ-
ence of miR-127-3p on the migration and invasion of
OS cells [62]. A single-nucleotide polymorphism (SNP),
namely polymorphism rs16917496 T>C, which is located
within the binding site of another miRNA, miR-502, in
SETD8 3′UTR, modulates SETD8 protein expression,
and thus contributes to susceptibility to breast and ovar-
ian cancer, and clinical outcome of small cell lung cancer
and hepatocellular carcinoma [63–66]. It has been
reported that the same SNP rs16917496 T>C contributes
to the survival of non-small cell lung cancer (NSCLC)
patients by altering SETD8 expression through
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modulating miRNA-target interaction [67] and is also
associated with decreased risk of developing pediatric
acute lymphoblastic leukemia (ALL) [68].
Ren, Sun, and coworkers demonstrated that SETD8
interacts with androgen receptor (AR) and that such
interaction and H4K20me1 levels are crucial for AR-me-
diated transcription activation of PSA (prostate-specific
antigen) gene [69].
Rice and coworkers reported a specific and direct
binding of SETD8 with the Riz1/PRDM2/KMT8 tumor
suppressor and showed that the N-terminal domain of
PRDM2 preferentially monomethylates H3K9, thus
establishing a H4K20me1-H3K9me1 trans-tail “histone
code” [70, 71]. Both SETD8 binding domain and methyl-
transferase activity are essential for PRDM2 tumor
suppressor function, and frameshift mutations resulting
in a truncated protein incapable of binding SETD8 are a
frequent hallmark of various aggressive cancers [70].
Besides its role in cancer diseases, it has been reported
that SETD8 is also involved in other physiological and
pathological processes, e.g. the regulation of erythroid
maturation [72]. Steiner and coworkers recently reported
that in erythroid cells, where expression levels of the
enzyme are significantly higher than in any other cell or
tissue type, SETD8 plays a crucial role as regulator of
erythroid maturation, functioning primarily as a repres-
sor of endothelial transcription factor GATA-2 expres-
sion. They showed that knockdown of SETD8 impair
erythroid maturation and result in a delay in hemoglobin
accumulation, larger mean cell area, persistent expres-
sion of mast/stem cell growth factor receptor CD117,
incomplete nuclear condensation, and lower rates of
enucleation, whereas cell proliferation or viability or
DNA damage are not affected [72]. At the same time,
following up their previous work establishing SETD8 as
a context-dependent GATA-1 corepressor [73], Bresnick
and coworkers demonstrated that SETD8 promotes the
maturation and survival of definitive erythroblasts
without involving upregulation of the established regula-
tor of erythroblast survival Bcl-xL. They showed that
SETD8-catalyzed H4K20me1 at a critical Gata2 cis
element restricts occupancy by Scl/TAL1, an enhancer
of Gata2 transcription, thus repressing Gata2 transcrip-
tion [74]. They also demonstrated that Gata2 repression
by SETD8 occurs in proerythroblasts, in which Gata2 is
not completely transcriptionally inactive, whereas in the
more mature basophilic erythroblast the gene is silenced
and insensitive to SETD8 downregulating effect. As a
consequence, they postulated a mechanism in which the
methyltransferase enzyme is required for initiation but
not maintenance of Gata2 repression [74].
Frye and coworkers reported that SETD8 is also neces-
sary for the maintenance of adult skin and is required
for c-Myc-induced epidermal proliferation [75]. In the
epidermis, during the development as well as in adult
skin, loss of SETD8 results in loss of proliferation and
impaired differentiation, accompanied by loss of the
interfollicular epidermis and sebaceous glands. The loss
of differentiation is a result of the lack of H4K20me1-
mediated activation of p63 gene, which is expressed in
basal cells and is thought to function as a master regula-
tor of the stratification of the developing epidermis. On
the other hand, the failure of Setd8-null skin to prolifer-
ate is mostly due to increased expression of p53, which
results in increased apoptosis in the basal layer of the
epidermis [75].
Other studies showed that adipogenesis is also epige-
netically regulated through H4K20 monomethylation
through a feedback loop [52]. In fact, Sakai and
coworkers reported that Setd8 gene is upregulated by
peroxisome proliferator-activated receptor γ (PPARγ)
and that the knockdown of the gene suppresses adipo-
genesis. Interestingly, they showed that toward the end
of differentiation SETD8-catalyzed H4K20me1 levels are
markedly increased and positively regulate the expres-
sion of PPARγ and its targets [52]. Furthermore, the
activation of PPARγ transcriptional activity leads to the
induction of H4K20me1 modification of the receptor
protein and its targets and thereby promotes adipogene-
sis. They also reported that H4K20me1 is involved into
the PPARγ2 targeting by PPARγ promoting its gene
expression [52].
PPARγ pathway is also important in the intrauterine
growth restriction (IUGR) that occurs when a fetus fails
to reach optimal growth potential in utero, frequently as
a result of maternal hypertensive disorders and uteropla-
cental insufficiency. IUGR and other insults occurring
during developmentally plastic periods cause neurodeve-
lopmental impairment and long-term neurological
morbidities that are evident as early as 2 years of age
and persist beyond school entry. In IUGR infants long-
term neurological morbidities are correlated with
changes in brain connectivity and reduced volume of the
hippocampus, a brain region key for the formation of
certain types of memory. Joss-Moore and coworkers
demonstrated that IUGR induces a reduction of the
levels of PPARγ, SETD8 and H4K20me1 in juvenile rat
hippocampus in conjunction with reduced Wnt signaling
[76]. Wnt3a, one of the Wnt signaling genes, is crucial
for normal growth of the hippocampus and regulate the
expansion of the caudomedial cortex, from which the
hippocampus develops. Moreover, Axin2, another Wnt
signaling target gene, is essential for myelination and
remyelination in brain development. Since canonical
Wnt/β-catenin signaling is activated by SETD8- cata-
lyzed H4k20me1 which is decreased in hippocampus,
the authors hypothesized that reduced PPARγ-SETD8-
H4K20me1 and Wnt signaling may contribute to altered
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hippocampal cellular composition which, in turn, may
contribute to impaired neurodevelopment and subse-
quent neurocognitive impairment in IUGR offspring
[76].
SETD8 inhibitors
Despite the importance of selective SETD8 inhibitors as
chemical probes to further investigate the cellular effects
of SETD8 inhibition in both normal and diseased cells
and as lead structures for the development of novel ther-
apeutics, only a limited number of such compounds
have been reported so far. Moreover, just a few of them
are endowed with a certain degree of selectivity.
The first reported inhibitors of SETD8 were two dye-
like compounds, H acid and thymolphthalein [77, 78],
described by Reinberg et al. in a 2007 patent [79]. The
two compounds were identified from the screening of a
small focused library [80–82] against three SET-
containing KMTs, SETD8, H3K9-specific G9a, and
H3K4-specific SETD7, as well as the H4R3-specific ar-
ginine methyltransferase PRMT1. Both of them showed
low IC50 values against nucleosomal KMTs SETD8 (3.8
and 9.0 μM, respectively) and EZH2 (3.0 and 25.2 μM,
respectively), while were inactive against the other tested
enzymes [79]. H acid is unable to enter cells, whereas
thymolphthalein induces a marked and concentration-
dependent reduction of HeLa cells viability and an evi-
dent reduction of global H4K20me1. Other histone
methylation marks are not affected. Also, the compound
induces a significant time- and concentration-dependent
enrichment of the mitotic population and abolishes the
DNA stimulatory effect on SETD8 methyltransferase
activity when octamers or H4-peptides are used as sub-
strates [79]. Thymolphthalein might possibly generate a
conformational change within the SET domain of the
enzyme that impairs catalysis or, otherwise, interfere
with the binding of the enzyme with the nucleosome
structure [24].
A few years later, Kodama et al. reported in another
patent the identification of a few compounds, namely
derivatives EBI-099, EBI-435 and EBI-455, from the vir-
tual screening of about 2 million compounds [83].
Among them, EBI-099 inhibits SETD8 (IC50 = 4.7 μM)
but not G9a and shows antiproliferative effects against
human myelogenous leukemia K562 cells [83].
In the context of a series of studies aimed at the identifi-
cation of epigenetic multiple ligands targeting different
enzymes [84, 85], in 2012, Mai and coworkers identified a
few bis(bromo- and dibromo-methoxylphenol) derivatives
as inhibitors of SETD8. Among them, derivatives MC1946
and MC1948 (indicated as compounds 5 and 10, respect-
ively, in the paper) are selective against SETD8, whereas
bis(monobromo) analogs MC1947 and MC2569 (indi-
cated as compounds 4 and 9, respectively, in the paper)
show dual SETD8 and EZH2 inhibition. The compounds
also reduce H4K20me1 levels in U937 cells, after 24-h
treatment at 50 μM. Compound MC1947 also induces
massive cell death and increases granulocytic differenti-
ation [86]. Since they contain an electrophilic α,β-unsatur-
ated carbonylic system, all MC derivatives could inhibit
SETD8 via a covalent binding.
In 2013, Andersen and coworkers isolated the polyke-
tide nahuoic acid A from cultures of a Streptomyces sp.
obtained from a marine sediment and reported its
inhibitory activity against SETD8 (IC50 = 6.5 ± 0.5 μM)
without any significant effect on the activity of other
protein methyltransferases such as G9a, EHMT1,
SETD7, SUV39H2, SUV420H1, SUV420H2, DOT1L,
PRMT3, and PRMT5 and MLL complexes [87]. Nahuoic
acid A competes with SAM binding (Ki = 2 ± 0.3 μM)
and is noncompetitive with respect to the binding of the
peptide substrate. Even if the structure of the compound
is rather polar, the authors have recently reported that
both nahuoic acid A and its pentaacetate analogue are
able to inhibit proliferation of several cancer cell lines in
vitro with modest potencies [88]. The compound also
appeared to selectively inhibit SETD8 in U2OS osteosar-
coma cells. A few analogs, nahuoic acids B–E [89],
differing from nahuoic acid A in the hydroxylation
patterns on the decalin ring system and in the length
and functionality of the C-13 side chain, show similar
inhibiting effects on SETD8 activity [88].
In 2014 Jin and coworkers identified compound
UNC0379 from the cross-screening against SETD8 of
their library of >150 quinazoline-based compounds tar-
geting lysine methyltransferases or methyllysine reader
proteins [90–94]. The compound inhibits SETD8 (IC50
= 7.3 ± 1.0 μM) and is competitive with the peptide sub-
strate and noncompetitive with the cofactor. Moreover,
it has been reported as selective for SETD8 over 15
other methyltransferases [95]. The authors also studied
the structure-activity relationships of UNC0379 and a
few analogs [96]. However, cellular activities have not
been reported.
Almost at the same time, Luo and coworkers identified
three SETD8 inhibitors from the screening of a library
consisting of more than 5000 commercially available
compounds [97]. The three compounds SPS8I1–3 (also
known as NSC663284, BVT948, and ryuvidine, respect-
ively) are potent inhibitors of SETD8 (apparent IC50
values of 0.21 ± 0.03, 0.50 ± 0.20, and 0.70 ± 0.20 μM,
respectively) and are not active against GLP, SETD7, and
PRMT1, with the exception of SPS8I2 that inhibits GLP
with IC50 of 4.70 ± 0.30 μM. Yet, the three compounds
inhibit SETD2, G9a, SMYD2, CARM1, and PRMT3 with
IC50 values in the low micromolar or submicromolar
range. Mechanistic studies suggested different mode of
action for the inhibition of SETD8 by SPS8I1 (substrate
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dependent), SPS8I2 (no substrate or SAM dependence),
and SPS8I3 (both substrate and SAM dependent) and
showed that SPS8I1–3 inhibits SETD8 via an irreversible
slow-onset process involving cysteine residues [97].
In human embryonic kidney HEK293T cells, the
compounds reduce H4K20me1 whereas other histone
marks (e.g., H4K20me2/3, H3K9me) are not affected and
produce a cell cycle arrest phenotype, similar to that of
SETD8 knockdown. In addition to the lack of selectivity
against other protein methyltransferases, a few off-target
effects on other cellular targets (inhibition of Cdc25 for
SPS8I1; inhibition of cyclin-dependent kinases 4 and 2
(CDK4/2) for SPS8I2; and inhibition of protein tyrosine
phosphatase PTB1B for SPS8I3) have been observed and
documented [97]. More recently, the same authors also
developed and patented a series of naphthoquinone deriv-
atives, the more active of them (namely compounds
SGSS05-N, SGSS05-NS, and SPECS-21) inhibit SETD8
with IC50 values ≤5 μM. Again, the compounds also
inhibit other KMTs (SETD2, SETDB1, GLP, G9a, SMYD2,
SMYD3, MLL1 and SETD7) and PRMTs (PRMT1,
PRMT3, CARM1, PRMT8) in the low micromolar range
[98].
Conclusions
An increasing number of reports on the key role played
by lysine methyltransferase SETD8 in physiological and
pathological pathways have appeared in literature during
the last decade. Many questions are still unsolved and
the effects of the enzyme in both normal and diseased
cells are still far from being completely understood, yet,
as described in this review, it is evident that SETD8
contributes to the regulation of transcriptional activity
and that it is implicated in many human diseases com-
prising cancer. However, regardless tremendous progress
in the discovery of selective, small-molecule inhibitors of
protein methyltransferases, only a limited number of
inhibitors have been reported so far for SETD8, with just
a few of them being endowed with a certain degree of
selectivity and/or cellular activity. Moreover, the struc-
tures of most of the inhibitors identified so far (if not all
of them) contain Pan Assay INterference compounds
(PAINS) [99, 100] motifs and, therefore, could exhibit
multiple behaviors that could interfere in assay readouts,
such as metal chelation, redox cycling, and protein
reactivity [101]. The improvement of these lead com-
pounds as well as the discovery of novel molecular scaf-
folds will hopefully help the investigation of the biology
of this emerging target and could lead to the develop-
ment of novel therapeutics. In this regard, the recent
identification of the domain used by SETD8 to bind and
methylate the nucleosome [24] could open the way to
design a new generation of allosteric inhibitors.
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